Ascendis Pharma A/S (ASND) income statement
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)
Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –
Ascendis Pharma A/S income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 91.3%
- Operating margin
- 25.4%
- Net margin
- 70.8%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 2.99
- Debt to equity
- –
- Debt to assets
- 16.8%
- Cash to current liabilities
- 174.7%
Valuation
- P/E ratio
- 22.2
- Price to sales
- 14.50
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?